Dublin, April 30, 2026 (GLOBE NEWSWIRE) — The “Oral Solid Dosage Contract Manufacturing Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The oral solid dosage contract manufacturing market has been experiencing significant growth, expanding from $42.39 billion in 2025 to an estimated $45.59 billion in 2026, reflecting a CAGR of 7.6%. This surge can be attributed to the increasing pressure on pharmaceutical companies to curb in-house manufacturing expenses, coupled with the complexity of oral solid dosage formulations and a boost in generic drug production. The limited internal manufacturing capacities in pharma companies and their growing reliance on third-party CMOs have also fueled this market expansion.
Looking ahead, the market is projected to reach $59.05 billion by 2030, reflecting a CAGR of 6.7%. This growth is largely driven by the demand for scalable manufacturing solutions and an expanding pipeline of oral solid dosage drugs. Further contributing factors include the push for advanced manufacturing technologies, a rise in pharmaceutical outsourcing, and a need for flexible production capabilities. Key trends include heightened outsourcing of manufacturing by pharmaceutical firms, demand for high-volume tablet and capsule production, and a shift towards modified release dosage forms. Additionally, there’s a growing emphasis on regulatory compliance and an increasing preference for comprehensive manufacturing and packaging services.
The generics sector plays a pivotal role in this market’s growth. Driven by patent expirations, cost-containment, regulatory incentives, and improved healthcare access, the demand for generic drugs has soared. Contract manufacturers support this by enhancing operational efficiency and accelerating time-to-market. For instance, the FDA approved over 35,000 generic drugs by 2025, with nearly 90% of prescriptions in generics, showing a clear trend towards generic dominance. The FDA’s extensive revised guidelines for generic drug production further illustrate this market’s trajectory.
The industry is also witnessing a focus on innovative solutions like continuous manufacturing lines, which streamline production by reducing downtime. WuXi STA, a prominent player, launched its first continuous line for oral solid pharmaceuticals in January 2023, marking a significant progress step in drug manufacturing. Similarly, in early 2025, Jabil Inc.’s acquisition of Pharmaceutics International, Inc. for $307 million aimed to bolster its capabilities in oral solid dosage forms, showcasing strategic industry maneuvers to enhance service offerings.
Prominent companies in this sector include Evonik Industries, Teva Pharmaceutical, Lonza Group, Catalent Inc., and Patheon Pharma. The Asia-Pacific region emerged as a market leader in 2025, with substantial activity in countries like China, India, and Japan.
Reasons to Purchase:
- Acquire a broad global outlook with an extensive report covering 16 key geographies.
- Examine the impact of macro factors such as geopolitical conflicts, trade policies, inflation, interest rates, and regulatory changes.
- Formulate regional and country-specific strategies using localized data and analysis.
- Identify lucrative growth segments for investment purposes.
- Utilize forecast data to surpass competition by understanding market drivers and trends.
- Gain insight into customer needs via end-user analysis.
- Benchmark against competitors by evaluating market share, innovation, and brand strength.
- Determine market potential through Total Addressable Market and Market Attractiveness Scoring.
- Support presentations with reliable, high-quality data and analysis.
- Receive the latest updates, along with an Excel data sheet for quick extraction and analysis.
Report Scope:
- Products: Tablets, Capsules, Powders, Granules, others
- Services: Drug Product Development, Fill Finish Manufacturing, API Manufacturing, and more
- Therapeutic Areas: Oncology, Cardiovascular, Metabolic Disorders, etc.
- End Users: Large, Medium, and Small Enterprises
Key Companies: Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Catalent Inc., and others.
Covered Geographies: Australia, Brazil, China, France, Germany, India, Japan, and more across Asia-Pacific and other major regions.
Time Series: Provides historical and forecast data over five and ten-year periods.
Data Insights: Offers ratios related to market size and growth, GDP proportions, and expenditure per capita.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $45.59 Billion |
| Forecasted Market Value (USD) by 2030 | $59.05 Billion |
| Compound Annual Growth Rate | 6.7% |
| Regions Covered | Global |
The companies featured in this Oral Solid Dosage Contract Manufacturing market report include:
- Evonik Industries AG
- Teva Pharmaceutical Industries Ltd.
- Lonza Group AG
- Catalent Inc.
- Patheon Pharma Services
- Fareva Holding SA
- Piramal Enterprises Limited
- Hetero Drugs Limited
- Siegfried Holding AG
- Recipharm AB
- Almac Group Limited
- Aenova Holding GmbH
- Jubilant Pharmova Limited
- Cambrex Corporation
- International Chemical Investors Group (ICIG) [operates under CordenPharma]
- Ajinomoto Co. Inc.
- Hovione Holding Ltd.
- Alcami Corporation
- NextPharma AB
- Delpharm
- PCI Pharma Services
- Adare Pharma
- Skyepharma
For more information about this report visit https://www.researchandmarkets.com/r/fgb1ss
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Oral Solid Dosage Contract Manufacturing Market
